ORAL ANTICOAGULANTS IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME

Abstract

The review discusses the results of using oral anticoagulants to improve the prognosis of patients after exacerbation of coronary artery disease. Based on a review of the available randomized clinical trials, the authors conclude that rivaroxaban at a dose of 2.5 mg twice daily has the best efficacy/safety ratio. Administration of rivaroxaban at the mentioned dose within 1 year after the development of acute coronary syndrome helps to reduce cardiovascular and total mortality and the risk of stent thrombosis.

Keywords

• acute coronary syndrome
• anticoagulants
• rivaroxa-ban
• stent thrombosis
• risk of bleeding